{"entity":{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","aka":[],"tldr":"A plain-language account of the KRYSTAL-12 trial, written for patients and carers, explaining how adagrasib compared with docetaxel chemotherapy in previously treated KRAS G12C lung cancer.","summary":"Plain language summary of the phase 3 KRYSTAL-12 trial, which randomised previously treated patients with KRAS G12C-mutated non-small-cell lung cancer to the KRAS G12C inhibitor adagrasib or docetaxel. Written by the trial investigators for a non-specialist reader, it restates the design, the progression-free survival result and the side-effect profile of the primary publication.\n\nEurope PMC indexes no abstract for this article, so OnCo carries no figures from it; the trial's own record holds the primary result from the pivotal publication.","asOf":"2026-09-21","links":[{"label":"Future Oncol 2026","url":"https://doi.org/10.1080/14796694.2026.2719409"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42745627/"},{"label":"ClinicalTrials.gov NCT04685135","url":"https://clinicaltrials.gov/study/NCT04685135"}],"tags":[],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":[],"targets":["kras"],"drugs":["adagrasib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["krystal-12"],"people":["fabrice-barlesi","lu-shun","martin-reck","tony-mok"],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"journal":"Future Oncology","year":2026,"doi":"10.1080/14796694.2026.2719409","pmid":"42745627","authors":"Barlesi F, Yao W, Duruisseaux M, et al.","paperType":"review","findings":["Restates the KRYSTAL-12 result in plain language for patients: adagrasib compared with docetaxel after prior treatment for KRAS G12C lung cancer."],"whatItMeans":"Useful for a patient offered adagrasib after chemotherapy or immunotherapy who wants the trial explained without jargon. It adds no new data; the primary KRYSTAL-12 publication and the trial page remain the reference for the numbers.","caveats":["A plain language summary of a published trial, not a new analysis; it reports no results beyond the primary publication.","No abstract is indexed on Europe PMC, so no figures have been transcribed here."],"changedPractice":false},"route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/"}],"person":[{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/"},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/"},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/"},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/"}],"journal":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/"}]}}